Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to identify a dose or doses of INS50589 intravenous infusion that are well-tolerated and which reduce postoperative bleeding and blood product transfusion.

• Phase: Phase 2

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: INS 50589

Criteria

Inclusion Criteria:

• Are scheduled for primary CABG by median sternotomy involving cardiopulmonary bypass

• Willing to receive allogeneic blood product transfusions during and after surgery

Exclusion Criteria:

• Have had previous cardiac surgery

• Have had previous median sternotomy

• Have tendency for bleeding or family history of bleeding

• Have an abnormally low platelet count

• Have received certain anticoagulant or antiplatelet medications within a specified time period prior to the scheduled CABG surgery